Daina Graybosch
Stock Analyst at Leerink Partners
(1.29)
# 3,709
Out of 5,130 analysts
98
Total ratings
42.65%
Success rate
-7.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPSC Century Therapeutics | Downgrades: Market Perform | $7 → $2 | $1.94 | +3.09% | 5 | Nov 17, 2025 | |
| IPHA Innate Pharma | Downgrades: Market Perform | $10 → $2 | $1.81 | +10.68% | 11 | Sep 18, 2025 | |
| XLO Xilio Therapeutics | Initiates: Outperform | $2 | $0.68 | +194.12% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $1.53 | +357.52% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $19.68 | -39.02% | 1 | Jun 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $110.53 | +7.66% | 19 | Jan 13, 2025 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $5.83 | +243.05% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $66.27 | -41.15% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $39.71 | +13.32% | 10 | Feb 24, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.05 | +852.38% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $21.01 | +80.87% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $4.10 | +95.12% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $99.85 | +124.34% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.09 | +1,335.41% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $0.60 | +2,716.90% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.88 | +378.72% | 4 | Feb 25, 2022 |
Century Therapeutics
Nov 17, 2025
Downgrades: Market Perform
Price Target: $7 → $2
Current: $1.94
Upside: +3.09%
Innate Pharma
Sep 18, 2025
Downgrades: Market Perform
Price Target: $10 → $2
Current: $1.81
Upside: +10.68%
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $2
Current: $0.68
Upside: +194.12%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $1.53
Upside: +357.52%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $19.68
Upside: -39.02%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $110.53
Upside: +7.66%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $5.83
Upside: +243.05%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $66.27
Upside: -41.15%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $39.71
Upside: +13.32%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.05
Upside: +852.38%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $21.01
Upside: +80.87%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $4.10
Upside: +95.12%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $99.85
Upside: +124.34%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.09
Upside: +1,335.41%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $0.60
Upside: +2,716.90%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.88
Upside: +378.72%